$ACON News

Aclarion Partners With Institute of Neuro Innovation on Back Pain Technology

Aclarion Announces That Its Nociscan Technology Was Used In A New Research Study Exploring The Biological Factors Associated With Back Pain In Patients With Modic Type 1 Changes

Ascendiant Capital Maintains Buy on Aclarion, Raises Price Target to $7.5

Echo Lake Capital Offers To Acquire Aclarion At $4.00/Share And Contingent Value Right Representing Right For Stockholders To Receive 80% Of Net Proceeds From Nociscan Sale.

Aclarion Q1 EPS $(1.34) Beats $(1.55) Estimate, Sales $21.140K Miss $25.000K Estimate

Aclarion Adds Lanman Spinal Neurosurgery As Clinical Site In CLARITY Trial

Aclarion Establishes Second Commercial Agreement With Weill Cornell Medicine; Deal Brings Nociscan To Weill Cornell Medicine And Och Spine At Newyork-Presbyterian/Weill Cornell Medical Center

Aclarion Announces $2.5M Buyback Plan

Aclarion Secures U.S. Patent Covering Machine Learning–Based Platform For Analyzing Magnetic Resonance Spectroscopy Data

Aclarion Signs Commercial Agreement With Weill Cornell Medicine Over Access For Nociscan To Weill Cornell, Och Spine

Ascendiant Capital Maintains Buy on Aclarion, Lowers Price Target to $7

Aclarion Adopts 1-Year Shareholder Rights Plan To Protect Long-Term Value And Prevent Hostile Takeovers

Aclarion Expands AI Tool To Help Doctors Pinpoint Back Pain, Eyes Growth As More Hospitals Adopt Nociscan Technology

Aclarion Publishes 2026 Shareholder Letter from the Chairman

Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation

Aclarion Expands Nociscan Availability In Los Angeles, Partners With Source Healthcare To Support Growth And Real-World Evidence Generation

Aclarion Raises $10.4 Million, Sharpens Focus On Nociscan Rollout

Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028

Aclarion Raises $10.4M, Extends Cash Runway Into 2028

Is the Market Bullish or Bearish on Aclarion Inc?